326
Views
4
CrossRef citations to date
0
Altmetric
Perspective

Considerations for ADHD in the child with epilepsy and the child with migraine

, &
Pages 861-869 | Received 07 Jul 2017, Accepted 24 Jul 2017, Published online: 07 Aug 2017

References

  • American Psychiatric Association. DSM-5 Task Force. Diagnostic and statistical manual of mental disorders DSM-5. 5th ed. Washington, DC: American Psychiatric Association; 2013.
  • American Psychiatric Association. Diagnostic and statistical manual of mental disorders text revision (DSM-IV-TR). 4th ed. Washington, DC: American Psychiatric Publishing, Inc; 2000.
  • Visser SN, Danielson ML, Bitsko RH, et al. Trends in the parent-report of health care provider-diagnosed and medicated attention-deficit/hyperactivity disorder: united States, 2003–2011. J Am Acad Adolesc Psychiatry. 2014;53:34–46.
  • Faraone SV, Sergeant J, Gillberg C, et al. The worldwide prevalence of ADHD: is it an American condition? World Psychiatry. 2003;2:104–113.
  • Barkley RA. Attention-deficit hyperactivity disorder a handbook for diagnosis and treatment. Fourth ed. New York: Guilford Press; 2015.
  • Willcutt EG, Doyle AE, Nigg JT, et al. Validity of the executive function theory of attention deficit/hyperactivity disorder: a meta-analytic review. Biol Psychiatry. 2005;57:1336–1346.
  • Shaw P, Stringaris A, Nigg J, et al. Emotion dysregulation in attention deficit hyperactivity disorder. Am J Psychiatry. 2014;171:276–293.
  • Cortese S, Castellanos FX. Neuroimaging of attention-deficit/hyperactivity disorder: current neuroscience-informed perspectives for clinicians. Curr Psychiatry Rep. 2012;14. DOI:10.1007/s11920-012-0310-y
  • Russell V, Allie S, Wiggins T. Increased noradrenergic activity in prefrontal cortex slices of an animal model for attention-deficit hyperactivity disorder–the spontaneously hypertensive rat. Behav Brain Res. 2000;117:69.
  • Dougherty DD, Bonab AA, Spencer TJ, et al. Dopamine transporter density in patients with attention deficit hyperactivity disorder. Lancet. 1999;354:2132.
  • Mazei-Robison MS, Blakely RD. ADHD and the dopamine transporter: are there reasons to pay attention?. Handb Exp Pharmacol. 2006;175:373–415.
  • Volkow ND, Wang G, Fowler JS, et al. Therapeutic doses of oral methylphenidate significantly increase extracellular dopamine in the human brain. J Neurosci. 2001;21:RC121.
  • Biederman J1, Faraone SV. Attention-deficit hyperactivity disorder. Lancet. 2005 Jul;16-22(366):237–248.
  • Nikolas MA1, Burt SA. Genetic and environmental influences on ADHD symptom dimensions of inattention and hyperactivity: a meta-analysis. J Abnorm Psychol. 2010Feb;119:1–17. DOI:10.1037/a0018010
  • Williams NM, Zaharieva I, Martin A, et al. Rare chromosomal deletions and duplications in attention-deficit hyperactivity disorder: a genome-wide analysis. Lancet. 2010;376:1401.
  • American Academy of Pediatrics. Subcommittee on attention-deficit/hyperactivity disorder, steering committee on quality improvement and management. ADHD: clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Pediatrics. 2011;128:000.
  • American Academy of Child and Adolescent Psychiatry (Pliszka S). Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2007;46:894–921.
  • Ruggiero S, Clavenna A, Reale L, et al. Guanfacine for attention deficit and hyperactivity disorder in pediatrics: a systematic review and meta-analysis. Eur Neuropsychopharmacol. 2014;24:1578–1590.
  • Fisher RS, Acevedo C, Arzimanoglou A, et al. ILAE official report: a practical clinical definition of epilepsy. Epilepsia. 2014;55:475.
  • Fisher RS, Cross JH, French JA, et al. Operational classification of seizure types by the international league against epilepsy: position paper of the ILAE Commission for classification and terminology. Epilepsia. 2017;58:522–530.
  • Scheffer IE, Berkovic S, Capovilla G, et al. ILAE classification of the epilepsies: position paper of the ILAE commission for classification and terminology. Epilepsia. 2017;58:512–521.
  • Russ SA, Larson K, Halfon N. A national profile of childhood epilepsy and seizure disorder. Pediatrics. 2012;129:256–264.
  • Williams AE, Guist JM, Kroenenberger WG, et al. Epilepsy and attention-deficit hyperactivity disorder: links, risks, and challenges. Neuropsych Dis Treat. 2016;12:287–296.
  • Hesdorffer DC, Ludvigsson P, Olafsson E, et al. ADHD as a risk factor for incident unprovoked seizures and epilepsy in children. Arch Gen Psychiatry. 2004;61:731–736.
  • Tovia E, Goldberg-Stern H, Ben Zeev B, et al. The prevalence of atypical presentations and comorbidities of benign childhood epilepsy with centrotemporal spikes. Epilepsia. 2011;52:1483–1488.
  • Kavros PM, Clarke T, Strug LJ, et al. Attention impairment in rolandic epilepsy: systematic review. Epilepsia. 2008;49:1570–1580.
  • Holtmann M, Becker K, Kentner-Figura B, et al. Increased frequency of rolandic spikes in ADHD children. Epilepsia. 2003;44:1241–1244.
  • Xiao F, Li L, An D, et al. Altered attention networks in benign childhood epilepsy with centrotemporal spikes (BCETS): a resting state fMRI study. Epilepsy Behav. 2015;45:234–241.
  • Vega C, Vestal M, DeSalvo M, et al. Differentiation of attention-related problems in childhood absence epilepsy. Epilepsy Behav. 2010;19:82–85.
  • Masur D, Shinnar S, Cnaan A, et al. Pretreatment cognitive deficits and treatment effects on attention in childhood absence epilepsy. Neurology. 2013;81:1572–1580.
  • Sherman EMS, Slick DJ, Connolly MB, et al. ADHD, neurological correlates and health-related quality of life in severe pediatric epilepsy. Epilepsia. 2007;48:1083–1091.
  • Hernandez M-T, Sauerwein HC, Jambaqué I, et al. Attention, memory, and behavioral adjustment in children with frontal lobe epilepsy. Epilepsy Behav. 2003;4:522–536.
  • Gottlieb L, Zelko FA, Kim DS, et al. Cognitive proficiency in pediatric epilepsy. Epilepsy Behav. 2012;23:146–151.
  • Gascoigne MB, Smith ML, Barton B, et al. Attention deficits in children with epilepsy: preliminary findings. Epilepsy Behav. 2016;67:7–12.
  • Jackson DC, Dabbs K, Walker NM, et al. The neuropsychological and academic substrate of new/recent-onset epilepsies. J Pediatr. 2013;162:1047–1053.
  • Dunn DW, Austin JK, Harzlak J, et al. ADHD and epilepsy in childhood. Dev Med Child Neurol. 2003;45:50–54.
  • Hermann B, Jones J, Dabbs K, et al. The frequency, complications and aetiology of ADHD in new onset paediatric epilepsy. Brain. 2007;130:3135–3148.
  • Jones JE, Watson R, Sheth R, et al. Psychiatric comorbidity in children with new onset epilepsy. Dev Med Child Neurol. 2007;49:493–497.
  • Almace D, Jones JE, Jackson DC, et al. The social competence and behavioral problem substrate of new- and recent-onset childhood epilepsy. Epilepsy Behav. 2014;31:91–96.
  • Aldenkamp A, Besag F, Gobbi G, et al. Adverse cognitive and behavioural effects of antiepileptic drugs in children. Epileptic Dis. 2016;18(Suppl 1):70–89.
  • Ekinci O, Isik U, Gunes S, et al. Understanding sleep problems in children with epilepsy: associations with quality of life, attention-deficit hyperactivity disorder and maternal emotional symptoms. Seizure. 2016;40:108–113.
  • Ekinci O, Isik U, Gunes S, et al. Self-concept in children and adolescents with epilepsy: the role of family functioning, mothers’ emotional symptoms and ADHD. Brain Dev. 2016;38:714–722.
  • Feldman H, Crumrine P, Handen BL, et al. Methylphenidate in children with seizures and attention-deficit disorder. Am J Dis Child. 1989;143:1081–1086.
  • Gonzalez-Heydrich J, Whitney J, Waber D, et al. Adaptive phase I study of OROS methylphenidate treatment of attention deficit hyperactivity disorder with epilepsy. Epilepsy Behav. 2010;18:229–237.
  • Adams J, Alipio-Jocson V, Inoyama K, et al. Methylphenidate, cognition, and epilepsy: a double-blind, placebo-controlled, single-dose study. Neurology. 2017;88:470–476.
  • Rheims S, Herbilon V, Villeneuve N, et al. ADHD in childhood epilepsy: clinical determinants of severity and of the response to methylphenidate. Epilepsia. 2016;57:1069–1077.
  • Semrud-Clikeman M, Wical B. Components of attention in children with complex partial seizures with and without ADHD. Epilepsia. 1999;40:211–215.
  • Bechtel N, Kobel M, Penner I-K, et al. Attention-deficit/hyperactivity disorder in childhood epilepsy: a neuropsychological and functional imaging study. Epilepsia. 2012;53:325–333.
  • Torres AR, Whitney J, Gonzalez-Heydrich J. Attention-deficit/hyperactivity disorder in pediatric patients with epilepsy: review of pharmacological treatment. Epilepsy Behav. 2008;12:141–152.
  • Radziuk AL, Kieling RR, Santos K, et al. Methylphenidate improves the quality of life of children and adolescents with ADHD and difficult-to-treat epilepsies. Epilepsy Behav. 2015;46:215–220.
  • Kledkiz AM, Dunn DW. Treatment of attention deficit hyperactivity disorder in children with medical comorbidities. Psychopharm Rev. 2010;45:49–55.
  • Bakhtadze S, Beridze M, Geladze N, et al. Effect of EEG biofeedback on cognitive flexibility in children with attention deficit hyperactivity disorder with and without epilepsy. Appl Psychophysiol Biofeedback. 2016;41:71–79.
  • Fuentes A, Kerr EN. Maintenance effects of working memory intervention (cogmed) in children with symptomatic epilepsy. Epilepsy Behav. 2017;67:51–59.
  • Parisi P, Verrotti A, Paolino MC, et al. Headache and attention deficit and hyperactivity disorder in children: common condition with complex relation and disabling consequences. Epilepsy Behav. 2014;32:72–75.
  • Strine TW, Okoro CA, McGuire LC, et al. The associations among childhood headaches, emotional and behavioral difficulties, and health care use. Pediatrics. 2006;117:1728–1735.
  • Fasmer OB1, Riise T, Lund A, et al. Comorbidity of migraine with ADHD. J Atten Disord. 2012 May;16:339–345.
  • Bigal ME, Arruda MA. Migraine in the pediatric population—evolving concepts. Headache. 2010;50:1130–1143.
  • Emilien G, Maloteaux JM, Geurts M, et al. Dopamine receptors —physiological understanding to therapeutic intervention potential. Pharmacol Ther. 1999;84:133–156.
  • Liston C, Malter Cohen M, Teslovich T, et al. Atypical prefrontal connectivity in attention-deficit/hyperactivity disorder: pathway to disease or pathological end point? Biol Psychiatry. 2011;69:1168–1177.
  • Toldo I, Perissinotto E, Menegazzo F, et al. Comorbidity between headache and epilepsy in a pediatric health center. J Headache Pain. 2010;11:325–340.
  • Haut SR, Bigal ME, Lipton RB. Chronic disorders with episodic manifestations: focus on epilepsy and migraine. Lancet Neurol. 2006;5:148–157.
  • Huang Y, Xiao H, Qin X, et al. The genetic relationship between epilepsy and hemiplegic migraine. Neuropsychiatr Dis Treat. 2017;13:1175–1179.
  • Villa TR, Agessi LM, Moutran AR, et al. Visual attention in children with migraine: the importance of prophylaxis. J Child Neurol. 2016 Apr;31:569–572.
  • Haas DC, Sheehe PR. Dextroamphetamine pilot crossover trials and n of 1 trials in patients with chronic tension-type and migraine headache. Headache. 2004;44:1029–1037.
  • Clavenna A, Bonati M. Safety of medicines used for ADHD in children: a review of published prospective clinical trials. Arch Dis Child. 2014;99:866–872.
  • Storebo OJ, Ramstad E, Krogh HB, et al. Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD) (Review). Cochrane Database Syst Rev. 2015;11:Art.No.CD009885.
  • Efron D, Jarman F, Barker M, et al. Side effects of methylphenidate and dextroamphetamine in children with attention deficit hyperactivity disorder: a double-blind, crossover trial. Pediatrics. 1997;100:662–666.
  • Pandolfo P, Machado NJ, Köfalvi A, et al. Caffeine regulates frontocorticostriatal dopamine transporter density and improves attention and cognitive deficits in an animal model of attention deficit hyperactivity disorder. Eur Neuropsychopharmacol. 2013;23:317–328.
  • Ioannidis K, Chamberlain SR, Müller U. Ostracizing caffeine from the pharmacological arsenal for attention-deficit hyperactivity disorder–was this a correct decision? A literature review. J Psychopharmacol. 2014 Sep;28:830–836.
  • Austin JK, Perkins SM, Johnson CS, et al. Behavioral problems in children at time of first recognized seizure and changes over the following 3 years. Epilepsy Behav. 2011;21:373–381.
  • Carlton-Ford S, Miller R, Brown M, et al. Epilepsy and children’s social and psychological adjustment. J Health Soc Behav. 1995;36:285–301.
  • McDermott S, Mani A, Krishnaswami S. A population-based analysis of specific behavior problems associated with childhood seizures. J Epilepsy. 1995;8:110–118.
  • Davies S, Heyman I, Goodman R. A population survey of mental health problems in children with epilepsy. Dev Med Child Neurol. 2003;45:292–295.
  • Turky A, Beavis JM, Thapar AK, et al. Psychopathology in children and adolescents with epilepsy: an investigation of predictive variables. Epilepsy Behav. 2008;12:136–144.
  • Chou IC, Chang YT, Chin ZN, et al. Correlation between epilepsy and attention deficit hyperactivity disorder: a population-based cohort study. PLoS One. 2013;8:e57926.
  • Cohen R, Senecky Y, Shuper A, et al. Prevalence of epilepsy and attention-deficit hyperactivity (ADHD) disorder: a population-based study. J Child Neurol. 2013;28:120–123.
  • Reilly C, Atkinson P, Das KB, et al. Neurobehavioral comorbidities in children with active epilepsy: a population-based study. Pediatrics. 2014;133:e1586–93.
  • Ottman R, Lipton RB, Ettinger AS, et al. Comorbidities of epilepsy: results from the Epilepsy Comorbidities and Health (EPIC) survey. Epilepsia. 2011;52:308–315.
  • Raj D, Kerr MP, McManus S, et al. Epilepsy and psychiatric comorbidity: a nationally representative population-based study. Epilepsia. 2012;53:1095–1103.
  • Ettinger AB, Ottman R, Lipton RB, et al. Attention-deficit/hyperactivity disorder symptoms in adults with self-reported epilepsy: results from a national epidemiologic survey of epilepsy. Epilepsia. 2015;56:218–224.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.